Bone marrow derived cd271 precursor cells for cardiac repair

Abstract

Methods for the isolation of CD271 + stem cell populations are important in the prevention or treatment of cardio-vascular diseases and repair of cardiac tissue. The methods are applicable to stem cells from different sources and can be used to treat or prevent diseases or repair of tissues elsewhere in the organism's body.

1 . A method of preventing or treating cardiovascular diseases or disorders comprising:
 isolating CD271 +  mesenchymal stem cell (MSC) precursor cells from bone marrow of a subject;   administering to a patient a therapeutically effective amount of isolated CD271 +  mesenchymal stem cell (MSC) precursor cells; and,   preventing or treating cardiovascular diseases or disorders.   
     
     
         2 . The method of  claim 1 , wherein the CD271 +  MSC precursor cells are isolated from bone marrow cells having a low affinity nerve growth receptor (NGFR; CD271). 
     
     
         3 . The method of  claim 1 , wherein the CD271 +  MSC precursor cells are isolated from donors comprising: autologous, syngeneic, allogeneic, or xenogeneic. 
     
     
         4 . The method of  claim 1 , wherein the CD271 +  MSC precursor cells differentiate into at least one lineage comprising: myocardial, vascular, or endothelial lineages. 
     
     
         5 . The method of  claim 1 , wherein the CD271 +  MSC precursor cells differentiate into lineages comprising: myocardial, vascular, or endothelial lineages. 
     
     
         6 . The method of  claim 4 , wherein the cardiomyocytes are identified by markers comprising: GATA-4, Nkx2.5 or a-sarcomeric actin. 
     
     
         7 . The method of  claim 4 , wherein the vascular cells are identified by markers comprising: a-smooth muscle actin or SMA22. 
     
     
         8 . The method of  claim 4 , wherein the endothelial cells are identified by markers comprising: CD31 or vimentin. 
     
     
         9 . The method of  claim 1 , wherein one or more agents are optionally administered to the patient, the agents comprising at least one of: cytokines, chemotactic factors, growth factors, or differentiation factors. 
     
     
         10 . The method of  claim 1 , wherein the cardiovascular diseases or disorders comprise: heart failure, atherosclerosis, ischemia, myocardial infarction, transplantation, hypertension, restenosis, angina pectoris, rheumatic heart disease, or congenital cardiovascular defect. 
     
     
         11 . The method of  claim 1 , wherein the CD271 +  MSC precursor cells are optionally administered to a patient in varying concentrations over a period of time. 
     
     
         12 . The method of  claim 1 , wherein the CD271 +  MSC precursor cells are engrafted in a heart in vivo in infarct and border zones. 
     
     
         13 . The method of  claim 1 , wherein the CD271 +  MSC precursor cells are optionally conditioned with media conditioned by heart derived stromal cells. 
     
     
         14 . The method of  claim 1 , wherein the CD271 +  MSC precursor cells are optionally cultured ex vivo and non-adherent precursor mesenchymal stem cells (NA-MSCs) are isolated, expanded and administered to a patient. 
     
     
         15 . The method of  claim 1 , wherein the CD271 +  MSC precursor cells are freshly isolated. 
     
     
         16 . The method of  claim 1 , wherein the CD271 +  MSC precursor cells are cultured under non-adherent conditions.